CompletedNot Applicable

Dalfampridine and Gait in Spinocerebellar Ataxias

United States20 participantsStarted 2013-02

Plain-language summary

Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals at age 18 years or older. * Individuals who can provide the informed consent * Genetic confirmed definite spinocerebellar ataxias (SCA) * Able to complete two trials of the timed 25-foot walk at screening Exclusion Criteria: * Patients who has severe ataxia and unable to ambulate. * Any orthopedic condition that would affect motor performance. * Patients with secondary ataxia from general medical disorders * Individuals who have major psychiatric disorders that prevents compliance * History of epilepsy * Patients with active drug or alcohol use or dependence that would interfere with adherence to study requirements * Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

What they're measuring

Change in Timed 25 Feet Walking Test (T25FW)

Timeframe: Baseline and 4 weeks after Dalfampridine or placebo

Trial details

NCT IDNCT01811706

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-12

Results submitted2014-12-10

View on ClinicalTrials.gov More Spinocerebellar Ataxias Type 1 trials